Clinical trials: Adult Atopic Dermatitis
Atopic Dermatitis
Efficacy of Fecal Microbial Transplantation Treatment in Adults With Atopic Dermatitis
Prospective single-blinded placebo-controlled cross-over study, among adult patients suffering from moderate-to-severe atopic dermatitis (AD), insufficiently responsive to topical and systemic treatment.
- Trial name
- NCT04613037
- Testing
- Fecal Microbial Transplantation
- Where
- Israel
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Dermatitis, Atopic
Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment
Long-term tacrolimus ointment based regimen comprising of up to 6 weeks of initial twice daily treatment and subsequent twice weekly prophylactic application can effectively treat active lesions of atopic dermatitis and prevent…
- Trial name
- NCT00480610
- Testing
- tacrolimus ointment
- Where
- 22 sites in Austria, Belgium and 11 more
- Volunteers
- 226 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis
Efficacy and Safety of Orally Administered DS107 in Adult Patients With Moderate to Severe Atopic Dermatitis
The objective of this study is to compare the efficacy and safety of orally administered DS107 (2g) versus placebo in the treatment of moderate to severe Atopic Dermatitis (AD).
- Trial name
- NCT03817190
- Testing
- DS107
- Where
- 50 sites in United States, Austria and 3 more
- Volunteers
- 219 people
- Sponsor
- DS Biopharma
Atopic Dermatitis
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device.
- Trial name
- Detect-AD (NCT07645820)
- Testing
- Nevisense electrical impedance spectroscopy
- Where
- 13 sites in United States
- Volunteers
- 450 people
- Sponsor
- Castle Biosciences Incorporated
Dermatitis, Atopic
Clinical Trial to Assess the Efficacy and Safety of Tacrolimus Ointment Treatment of Atopic Dermatitis in Adult Patients
Objective: Assess efficacy and safety of tacrolimus ointment when used in adults with moderate or severe atopic dermatitis. The ointment was applied on the affected skin twice daily for 3 weeks and then once daily until all…
- Trial name
- NCT00523952
- Testing
- tacrolimus ointment
- Where
- 25 sites in Czechia, Hungary and 1 more
- Volunteers
- 303 people
- Sponsor
- Astellas Pharma Inc
Atopic Dermatitis (AD)
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
The primary objective of the study was to assess the efficacy of Dupilumab, compared to placebo, in adult patients with moderate-to-severe atopic dermatitis (AD).
- Trial name
- NCT01979016
- Testing
- Dupilumab, Background treatment
- Where
- 4 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Regeneron Pharmaceuticals
Dermatitis, Atopic, Eczema
Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis
The purpose of this study is to compare the effects of an amino acid moisturizing cream and desonide cream in reducing skin symptoms associated with AD/eczema in subjects with mild to moderate atopic dermatitis/eczema.
- Trial name
- NCT02286700
- Testing
- Desonide Cream, Amino Acid Moisturizing Cream
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- NeoStrata Company, Inc.
Atopic Dermatitis
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
The primary objective for this study is to evaluate the safety of lebrikizumab compared with Topical Corticosteroids (TCS) alone in patients with persistent moderate to severe Atopic Dermatitis (AD) that is inadequately…
- Trial name
- NCT02465606
- Testing
- Lebrikizumab, Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
- Where
- 19 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Hoffmann-La Roche
Atopic Dermatitis Eczema
Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients
Unlike healthy control skin, the skin of patients with atopic dermatitis (AD) is frequently colonized by Staphylococcus aureus (S. aureus), putting these patients at increased risk of S. aureus skin infections.
- Trial name
- NCT03158012
- Testing
- Autologous Microbial Transplant
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, San Diego
Chronic Hand Eczema
Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2)
This was a 16-week study in adult participants with chronic hand eczema (CHE). The participants visited the clinic regularly to have the study doctor assess their CHE and to answer questions about itch, pain, CHE symptoms, and…
- Trial name
- DELTA 2 (NCT04872101)
- Testing
- Delgocitinib cream, Cream vehicle
- Where
- 50 sites in Belgium, Canada and 5 more
- Volunteers
- 473 people
- Sponsor
- LEO Pharma
Staphylococcus Aureus, Atopic Dermatitis
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis
Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder, with a lifetime prevalence of 15-25% in children and 1-3% in adults worldwide.
- Trial name
- NCT05092464
- Testing
- Natural Lactic Acid-enriched Cream
- Volunteers
- 10 people
- Sponsor
- Microbio Co Ltd
Atopic Dermatitis
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
This is a randomized, double-blind, double-dummy, active-controlled, multi-center study to assess the efficacy and safety of abrocitinib 200 mg (2 x 100 mg tablets) administered orally QD compared with dupilumab 300 mg…
- Trial name
- NCT04345367
- Testing
- Abrocitinib 200 mg, Dupilumab 300 mg
- Where
- 151 sites in United States, Australia and 13 more
- Volunteers
- 727 people
- Sponsor
- Pfizer
Atopic Dermatitis
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.
- Trial name
- NCT04212169
- Testing
- MEDI3506
- Where
- 38 sites in United States, Australia and 4 more
- Volunteers
- 148 people
- Sponsor
- AstraZeneca
Atopic Dermatitis
Evaluation of FB-401 in Children, Adolescents and Adults (2 Years and Older) With Mild to Moderate Atopic Dermatitis
The purpose of this study is to evaluate the potential improvement in atopic dermatitis signs and symptoms following the application of FB-401 in patients 2 years or older with mild to moderate atopic dermatitis.
- Trial name
- NCT04504279
- Testing
- FB-401
- Where
- 15 sites in United States
- Volunteers
- 154 people
- Sponsor
- Forte Biosciences, Inc.
Atopic Dermatitis
Evaluate Efficacy, PK, and Safety of FB825 in Adults With Atopic Dermatitis
The study aims to evaluate the efficacy, improvement from baseline in Eczema Area and Severity Index (EASI) score, of multiple intravenous (IV) doses of FB825 in subjects with atopic dermatitis
- Trial name
- NCT04413942
- Testing
- FB825
- Where
- 18 sites in United States
- Volunteers
- 99 people
- Sponsor
- Oneness Biotech Co., Ltd.
Atopic Dermatitis
A First-in-Human Study of CEE321 in Adult Subjects
Open label, non-randomized, uncontrolled, First-in-Human Phase 1 Study in Healthy Subjects and Subjects with Atopic Dermatitis
- Trial name
- NCT04612062
- Testing
- CEE321
- Where
- 3 sites in United States, Japan
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis
An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how effective upadacitinib is in treating AD. Upadacitinib is an approved drug for treating AD.
- Trial name
- UPDATE (NCT05669794)
- Where
- 59 sites in France
- Volunteers
- 300 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.
This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate Food effect of VC005 Tablets in healthy subjects
- Trial name
- NCT07533851
- Testing
- VC005 Tablets
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Dermatitis, Atopic, Eczema
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
The main purpose of this study is to evaluate the efficacy of lebrikizumab compared with placebo in participants not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable up to Week 16.
- Trial name
- ADvantage (NCT05149313)
- Testing
- Lebrikizumab
- Where
- 48 sites in Austria, Belgium and 6 more
- Volunteers
- 331 people
- Sponsor
- Almirall, S.A.
Chronic Hand Eczema
Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema
The purpose of the trial is to test how much delgocitinib enters the body over a given time period after application of delgocitinib cream in patients with moderate to severe hand eczema.
- Trial name
- NCT05486117
- Testing
- Delgocitinib
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- LEO Pharma